Want to see GILD full AI Analyst Report?
Total Valuation
Gilead Sciences has a market cap or net worth of $205.35B. The enterprise value is $178.32B.
Market Cap$205.35B
Enterprise Value$178.32B
Share Statistics
Gilead Sciences has 1,239,955,200 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,239,955,200
Owned by Insiders0.08%
Owned by Institutions2.63%
Financial Efficiency
Gilead Sciences’s return on equity (ROE) is 0.37 and return on invested capital (ROIC) is 20.32%.
Return on Equity (ROE)0.37
Return on Assets (ROA)0.14
Return on Invested Capital (ROIC)20.32%
Return on Capital Employed (ROCE)0.25
Revenue Per Employee1.73M
Profits Per Employee500.59K
Employee Count17,000
Asset Turnover0.50
Inventory Turnover3.51
Valuation Ratios
The current PE Ratio of Gilead Sciences is ―. Gilead Sciences’s PEG ratio is 0.01.
PE Ratio―
PS Ratio5.19
PB Ratio6.73
Price to FCF16.15
Price to Operating Cash Flow14.21
PEG Ratio0.01
Income Statement
In the last 12 months, Gilead Sciences had revenue of 29.44B and earned 8.51B in profits. Earnings per share was 6.84.
Revenue29.44B
Gross Profit23.21B
Operating Income11.70B
Pretax Income9.80B
Net Income8.51B
EBITDA13.58B
Earnings Per Share (EPS)6.84
Cash Flow
In the last 12 months, operating cash flow was 14.48B and capital expenditures -699.00M, giving a free cash flow of 14.27B billion.
Operating Cash Flow14.48B
Free Cash Flow14.27B
Free Cash Flow per Share11.51
Dividends & Yields
Gilead Sciences pays an annual dividend of $0.82, resulting in a dividend yield of 1.96%
Dividend Per Share$0.82
Dividend Yield1.96%
Payout Ratio38.47%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.33
52-Week Price Change43.28%
50-Day Moving Average150.05
200-Day Moving Average138.38
Relative Strength Index (RSI)70.04
Average Volume (3m)5.99M
Important Dates
Gilead Sciences upcoming earnings date is Feb 4, 2027, After Close (Confirmed).
Last Earnings DateOct 29, 2026
Next Earnings DateFeb 4, 2027
Ex-Dividend Date―
Financial Position
Gilead Sciences as a current ratio of 1.55, with Debt / Equity ratio of 0.00%
Current Ratio1.55
Quick Ratio1.40
Debt to Market Cap0.16
Net Debt to EBITDA1.28
Interest Coverage Ratio11.43
Taxes
In the past 12 months, Gilead Sciences has paid 1.29B in taxes.
Income Tax1.29B
Effective Tax Rate0.13
Enterprise Valuation
Gilead Sciences EV to EBITDA ratio is 12.52, with an EV/FCF ratio of 17.98.
EV to Sales5.78
EV to EBITDA12.52
EV to Free Cash Flow17.98
EV to Operating Cash Flow16.97
Balance Sheet
Gilead Sciences has $6.44B in cash and marketable securities with $2.42B in debt, giving a net cash position of $4.02B billion.
Cash & Marketable Securities$6.44B
Total Debt$2.42B
Net Cash$4.02B
Net Cash Per Share$3.24
Tangible Book Value Per Share-$2.15
Margins
Gross margin is 58.48%, with operating margin of 39.74%, and net profit margin of 28.90%.
Gross Margin58.48%
Operating Margin39.74%
Pretax Margin33.27%
Net Profit Margin28.90%
EBITDA Margin46.12%
EBIT Margin36.75%
Analyst Forecast
The average price target for Gilead Sciences is $171.81, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$171.81
Price Target Upside15.49% Upside
Analyst ConsensusStrong Buy
Analyst Count22
Revenue Growth Forecast6.05%
EPS Growth Forecast-151.43%